Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
An artistic rendition of stabilized antibody-drug conjugates in the blood. Lyon et al. describe a linker chemistry that increases the stability and efficacy of antibody-drug conjugates in vivo (p 1059). Credit: Kenneth Eward
Drug delivery research requires an injection of new thinking. Fostering closer ties with cell biologists seeking to unravel membrane trafficking is a good place to start.
Big pharma's storehouse of trouble has fostered consumer mistrust and a negative view of the industry. How does the industry go about restoring its flagging reputation?
Monoclonal antibodies continue their march on the markets, optimized so-called biobetter versions of existing biologics are also gaining ground, but the rate of biosimilar approvals has seen a dramatic slowdown in recent years.
An elegant mathematical model supported by experiments in Escherichia coli demonstrates how clustering enzymes can efficiently channel intermediates from one enzyme to the next, facilitating rational engineering of metabolism.
Coupling limited proteolysis and a proteomics workflow enables measurement of both subtle and wholesale protein conformational changes in a eukaryotic proteome.
At Washington University, students and faculty have addressed challenges surrounding biomedical innovation and training through a novel and low-cost platform.
